Induction of estrogen receptor-α and -β activities by synthetic progestins

Gynecological Endocrinology

Volumn 14, Issue 2, 2000, Pages 118-126

  Rabe, T ^a,b   Bohlmann, M K ^a   Rehberger Schneider, S ^a   Prifti, S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Estrogen receptor ; Estrogen receptor ; Progestins

Indexed keywords

DESOGESTREL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; LUCIFERASE; NORETHISTERONE; NORETYNODREL;

ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE ACTIVITY; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REPORTER GENE;

EID: 0034108015     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513590009167670     Document Type: Article

References (44)

1. 1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59
2. 2. Pike M, Henderson BE, Krailo MD, et al. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983;2:926-9
3. 3. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-46
4. 4. Kalkhoven E, Kwakkenbos-Isbrücker L, de Laat SW, et al. Synthetic progestins induce proliferation of breast cancer cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol 1994;102: 45-52
5. 5. Lin VCL, Ng EH, Aw SE, et al. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 1999;5:395-403
6. 6. Byrne MJ, Gebski V, Forbes J, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J Clin Oncol 1997;15:3141-8
7. 7. Hultborn R, Johanssonterje I, Bergh J, et al. Second line endocrine treatment of advanced breast cancer: a randomized cross-over study of MPA and aminoglutethimide. Acta Oncol 1996;35:75-81
8. 8. Graham JD, Roman SD, MaGowan E, et al. Preferential stimulation of human progesterone receptor B expression by estrogen in T47-D human breast cancer cells. J Biol Chem 1995;270:30693-700
9. 9. Alexander IE, Shine J, Sutherland RL. Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells. Mol Endocrinol 1990;4: 821-8
10. 10. Poulin R, Baker D, Poirier D, et al. Multiple actions of synthetic progestins on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat 1990;17:197-210
11. 11. Brandenberger AW, Tee MK, Lee JY, et al. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab 1997;82: 3509-12
12. 12. Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999;59:5421-4
13. 13. Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 1999; 59:5425-8
14. 14. Speirs V, Parkers AT, Kerin MJ, et al. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res 1990;59:525-8
15. 15. Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 1999;59:1175-9
16. 16. Fiorelli G, Picariello L, Martinetti V, et al. Functional estrogen receptor β in colon cancer cells. J Biochem Biophys Res Commun 1999;261:521-7
17. 17. Carrol RS, Zhang J, Black PM. Expression of estrogen receptors α and β in human meningiomas. J Neurooncol 1999;42:109-16
18. 18. Kasid A, Lippman ME. Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem 1987;27:465-70
19. 19. Jordan VC, ed. Estrogen-Antiestrogen Action and Breast Cancer Therapy. Madison: University of Wisconsin Press, 1986:132-43
20. 20. Weisz A, Bresciani F. Estrogen regulation of protooncogenes coding for nuclear proteins. Crit Rev Oncogen 1993;4:361-88
21. 21. Planas-Silva MD, Weinberg RA. Estrogen dependent cyclinE-cdk2 activation through p21 redistribution. Mol Cell Biol 1997;17:4059-69
22. 22. Musgrove EA, Hamilton JA, Lee CS, et al. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T47-D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-87
23. 23. Kumar V, Green S, Staub A, et al. Localisation of the estradiol-binding domains of the human estrogen receptor. EMBO J 1986;5:2231-6
24. 24. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93:5925-30
25. 25. Pettersson K, Grandien K, Kuiper GG, et al. Mouse estrogen receptor beta forms estrogen response element binding heterodimers with estrogen receptor alpha. Mol Endocrinol 1997;11:1486-96
26. 26. Hall JM, McDonnell DP. The estrogen receptor-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogen and antiestrogens. Endocrinology 1999;140:5566-78
27. 27. Fuhrmann U, Slater EP, Fritzemeier KH. Characterisation of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception 1995;51:45-52
28. 28. Haller DG, Click JH. Progestational agents in advanced breast cancer: an overview. Semin Oncol 1986;13:2-8
29. 29. Byrne MJ, Gebski V, Forbes J, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J Clin Oncol 1997;3:3141-8
30. 30. Hultborn R, Johanssonterje I, Bergh J, et al. Second-line endocrine treatment of advanced breast cancer: a randomized cross-over study of medroxyprogesterone acetate and aminoglutethimide. Acta Oncol 1996;35:75-9
31. 31. Poulin R, Dufour JM, Labrie F. Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin. Breast Cancer Res Treat 1989;13:265-76
32. 32. Jordan VC, Jeng MH, Catherino WH, et al. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer 1993;71:1501-5
33. 33. Huggins C, Yang NC. Induction and extinction of mammary cancer. Science 1962;137:257-62
34. 34. Asselin J, Kelly PA, Caron MG, et al. Control of hormone receptor levels and growth of 7,12-dimethylbenzanthracene-induced mammary tumors by estrogen, progesterone, and prolactin. Endocrinology 1977;101:666-71
35. 35. Schoonen WG, Joosten JW, Klosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives on cell growth of human breast tumor cells. J Steroid Biochem Mol Biol 1995;55:439-44
36. 36. Alexieva-Figusc J, Teulings FA, Hop WC, et al. Steroid receptors in megestrol acetate therapy. Rec Results Cancer Res 1984;91:253-8
37. 37. Ettinger DS, Allegra J, Bertino JR, et al. Megestrol acetate vs. tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986;13:9-14
38. 38. Raynaud JP, Ojasoo T, Labrie F. Steroid agonists and antagonists. In Lewis GP, Grisburg M, eds. Mechanism of Steroid Action. London: MacMillan Press, 1981:145-58
39. 39. Van Kordelaar JM, Vermorken AJ, de Weerd CJ. Interaction of contraceptive progestins and related compounds with the estrogen receptor. Acta Androcr Copenh 1975;78:165-79
40. 40. Vilchis F, Chavez B, Perez AE, et al. Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progesterone receptors. J Steroid Biochem 1986;24:525-31
41. 41. Larrea F, Vilchis F, Chavez B, et al. The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level. J Steroid Biochem 1987;27:657-63
42. 42. Fortunati N, Fissore F, Comba A. Sex steroid-binding protein and its membrane receptor in estrogen-dependent breast cancer: biological and pathophysiological impact. Horm Res 1996;45: 202-6
43. 43. Maggi R, Poletti A, Casulari LA, et al. Effects and metabolism of steroid hormones in human neuroblastoma cells. Steroids 1998;63:257-62
44. 44. van der Brule FA, Engel J, Stetler-Stevenson WG, et al. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer 1992;52:653-7